Clinical trials: Treatment Resistant
Ovarian Neoplasms
TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations.
- Trial name
- NCT00057720
- Testing
- TLK286 HCl for injection, topotecan hydrochloride for injection, doxorubicin HCl liposome injection
- Where
- 320 sites in United States, Argentina and 11 more
- Volunteers
- 440 people
- Sponsor
- Telik
Prostate Cancer
Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
This multicenter, international, Phase Ib/II trial consists of three stages: a Phase Ib, open-label stage in which the recommended Phase II dose was determined for ipataseritib administrated in combination with abiraterone and of…
- Trial name
- NCT01485861
- Testing
- Abiraterone, Apitolisib, Ipatasertib
- Where
- 59 sites in United States, Czechia and 7 more
- Volunteers
- 298 people
- Sponsor
- Genentech, Inc.
Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis
Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis
The purpose of this study is to determine whether nalfurafine hydrochloride is effective and safe in the treatment for conventional-treatment-resistant pruritus in patients receiving hemodialysis.
- Trial name
- TRK-820 (NCT01513161)
- Testing
- nalfurafine hydrochloride (TRK-820)
- Where
- South Korea
- Volunteers
- 104 people
- Sponsor
- SK Chemicals Co., Ltd.
Bacterial Infections
New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)
This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)
- Trial name
- NCT00035854
- Testing
- Zyvox® / Linezolid
- Where
- 21 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer
Metastatic Castration-Resistant Prostate Cancer
A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
The objective of this study was to evaluate the efficacy and safety of enzalutamide treatment in patients with progressive metastatic castration-resistant prostate cancer previously treated with abiraterone acetate.
- Trial name
- NCT02116582
- Testing
- Enzalutamide
- Where
- 50 sites in Belgium, France and 3 more
- Volunteers
- 215 people
- Sponsor
- Astellas Pharma Europe B.V.
Adverse Drug Event, Effect of Drug
Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus
Objective: To evaluate the safety and efficacy of Human Insulin rDNA (Insuget) in patients with Type II Diabetes Mellitus. Study Design: Open-label, prospective, observational, single arm, multi-center, post-marketing…
- Conditions
- Adverse Drug Event, Effect of Drug, Type 2 Diabetes Treated With Insulin
- Trial name
- RISE (NCT05161741)
- Testing
- Insulin
- Where
- Pakistan
- Volunteers
- 238 people
- Sponsor
- Getz Pharma
Patients, Resistant Hypertension
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
The purpose of the present study was to determine whether LHW090 displays the clinical safety and efficacy profile to support further development in patients with resistant hypertension.
- Trial name
- NCT02515331
- Testing
- LHW090
- Where
- 16 sites in United States, Denmark and 4 more
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Influenza
A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal Influenza
This open-label randomized 2 arm study will determine the emergence of viral resistance in participants with seasonal influenza A infection treated with oseltamivir.
- Trial name
- NCT00949533
- Testing
- Oseltamivir
- Where
- 3 sites in Brazil
- Volunteers
- 37 people
- Sponsor
- Hoffmann-La Roche
Metastatic Castration-Resistant Prostate Cancer, mCRPC
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants
This study will test an experimental Regeneron drug called REGN21353 ("study drug") to see if it can help treat previously treated prostate cancer that has spread (also called metastatic castration-resistant prostate cancer or…
- Trial name
- NCT07850921
- Testing
- REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency)
- Volunteers
- 192 people
- Sponsor
- Regeneron Pharmaceuticals
Hypertension
Observational Study to Investigate Resistant Hypertension Prevalence in Korean General Hospitals
Study Objectives The study is to identify prevalence, demography and clinical characteristics of patients with resistant hypertension among hypertensive patients who have been treated in general hospitals in Korea from Jan 2012…
- Trial name
- Teveten_RH (NCT01753206)
- Where
- South Korea
- Volunteers
- 1,579 people
- Sponsor
- Handok Inc.
Prostatic Neoplasms, Castration-Resistant
Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.
- Trial name
- Navigant (NCT02899104)
- Testing
- Xofigo (Radium-223 dichloride, BAY88-8223)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Bayer
Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer
Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer
Epithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm.
- Conditions
- Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer, Platinum-Resistant FRα-Positive Peritoneal Cancer
- Trial name
- MIRELA (NCT07896421)
- Where
- Austria
- Volunteers
- 500 people
- Sponsor
- AbbVie
Staphylococcal Skin Infections
Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA
This was a real-world, prospective, open-label, multicenter study in which participants were randomized (1:1) to receive intravenous (IV) vancomycin or IV daptomycin.
- Trial name
- DAPHEOR1006 (NCT01419184)
- Testing
- Daptomycin, Vancomycin
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 250 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Epilepsy
Non-interventional Study Describing Healthcare Resource Utilisation and Clinical Outcomes Associated With VNS Therapy in UK.
This is a UK, multi-center, non-interventional study based on the use of health service administrative and medical records (paper-based and/or electronic, as applicable) along with the use of prospectively collected…
- Trial name
- DANTE (NCT04779814)
- Where
- 5 sites in United Kingdom
- Volunteers
- 97 people
- Sponsor
- LivaNova
Depressive Disorder, Treatment-Resistant
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms…
- Trial name
- SUSTAIN-1 (NCT02493868)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 155 sites in United States, Belgium and 13 more
- Volunteers
- 719 people
- Sponsor
- Janssen Research & Development, LLC
Partial Epilepsy
Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
This study is to evaluate the efficacy of YKP3089 in reducing seizure frequency when compared to baseline in subjects with partial onset seizures not fully controlled despite their treatment with 1 to 3 concomitant anti-epileptic…
- Trial name
- NCT01397968
- Testing
- YKP3089
- Where
- 38 sites in United States, India and 2 more
- Volunteers
- 222 people
- Sponsor
- SK Life Science, Inc.
Infection, Human Immunodeficiency Virus
Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations
This trial is a randomized, double-blind, placebo-controlled clinical study conducted in treatment-experienced adults with NNRTI-resistant HIV-1, designed to preliminarily evaluate the efficacy, safety, and resistance profile of…
- Trial name
- NCT07711210
- Testing
- ACC017
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Castration-resistant Prostate Cancer
A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer
This study will first conduct a phase II clinical study, and on the basis of the phase II clinical study, subsequent clinical research will be carried out.
- Trial name
- NCT07641855
- Testing
- BL-B01D1, Abiraterone, Olaparib
- Where
- 2 sites in China
- Volunteers
- 180 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Diabetes
Efficacy and Safety of Frequently Modified Intensive Insulin
The purpose of this study is to evaluate the efficacy and safety of frequently modified intensive insulin therapy in patients with Type-2 and Type-1 diabetes mellitus.
- Trial name
- NCT01014832
- Testing
- Intensive insulin therapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Hygieia, Inc
Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC)
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
This is a multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of B1962 in the treatment of ad-vanced solid tumors.
- Conditions
- Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer
- Trial name
- NCT06724263
- Testing
- B1962
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.